证券代码：688193 证券简称：仁度生物 公告编号：2025-049 上海仁度生物科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 17 日 （二） 股东大会召开的地点：上海市浦东新区瑞庆路 528 号 15 幢公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 24 | | --- | --- | | 普通股股东人数 | 24 | | 2、出席会议的股东所持有的表决权数量 | 17,246,554 | | 普通股股东所持有表决权数量 | 17,246,554 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 44.4746 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 44.4746 | ...

R YE UNE BE A PT YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海仁度生物科技股份有限公司 北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 2025年第一次临时股东大会的 法律意见书 嘉源(2025)-04-835 北京市嘉源律师事务所(以下简称"本所")接受上海仁度生物科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《上海仁度生物科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司 2025年第一次临时股东大会(以下简称"本次 股东大会"）进行见证,并依法 ...

Core Points - Shanghai Rendu Biotechnology Co., Ltd. announced a change in its continuous supervision sponsor representative due to the work relocation of the original representative [2] - China International Capital Corporation (CICC) is the sponsor for the company's initial public offering (IPO) and listing on the Sci-Tech Innovation Board, with the continuous supervision period lasting until December 31, 2025 [2] - Yang Wei has been appointed as the new sponsor representative to ensure the orderly continuation of supervision work [2]

关于公司变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）于近日收到公司保荐 机构中国国际金融股份有限公司（以下简称"中金公司"）出具的《关于上海仁 度生物科技股份有限公司变更持续督导保荐代表人的函》。 中金公司为公司首次公开发行股票并在科创板上市项目的保荐人，原指定范 钰坤先生、魏德俊先生为公司首次公开发行股票项目保荐代表人，负责保荐工作 及持续督导工作，持续督导期至 2025 年 12 月 31 日。现因范钰坤先生工作变动， 无法继续从事对公司的持续督导工作。为保证持续督导工作的有序进行，中金公 司现委派保荐代表人杨唯女士（简历见附件）接替范钰坤先生继续履行持续督导 工作。 上海仁度生物科技股份有限公司 证券代码：688193 证券简称：仁度生物 公告编号：2025-048 上海仁度生物科技股份有限公司 董事会 2025 年 11 月 13 日 附：杨唯女士简历 杨唯女士，保荐代表人，现任中国国际金融股份有限公司投资银行部副总 经理，曾经主持或参与 ...

Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688193 证券简称：仁度生物 上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 11 月 上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 议案一 | 关于公司变更注册资本、取消监事会并修订《公司章程》的议案 | 6 | | --- | --- | --- | | 议案二 | 关于公司修订部分内部管理制度的议案 | 8 | | 议案三 | 关于公司为董事、高级管理人员购买责任保险的议案 | 9 | 上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"证券法"）《上市公司股东大会规则》以及《上 海仁度生物科技股份有限公司章程》（以下简称"《公司章程》"）《上海仁度生 物科技股份有限公司股东大会议事规则》等相关规定，上海仁度生物科技股份 ...

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Core Insights - RenDu Bio (688193.SH) reported its Q3 2025 results on October 31, 2025, highlighting a total of 6 institutional investors holding shares, amounting to 13.6487 million shares, which represents 34.06% of the total share capital [1] Institutional Holdings - The total institutional holding percentage decreased by 3.26 percentage points compared to the previous quarter [1] - The institutional investors include MING LI INVESTMENTS LIMITED, Changzhou Jin Xin Venture Capital Co., Ltd., CENTRAL CHIEF LIMITED, Runcong (Shanghai) Enterprise Management Center (Limited Partnership), Nanjing Gaoke Xinjun Growth Phase I Equity Investment Partnership (Limited Partnership), and CICC-Pudong Development Bank-CICC Fengzhong No. 41 Employee Participation in Sci-Tech Innovation Board Strategic Allocation Collective Asset Management Plan [1] Public Fund Activity - A total of 31 public funds were disclosed this period, including Huaxia Pantai Mixed (LOF) A, Huaxia New Jinxiu Mixed A, GF Multi-Factor Mixed, Huashang Quantitative Quality Selected Mixed, and E Fund Shanghai Stock Exchange Sci-Tech Innovation Board Comprehensive ETF [1] Foreign Investment Trends - One foreign fund, CENTRAL CHIEF LIMITED, reduced its holdings by 1.00% compared to the previous quarter [1]

Core Insights - The company reported a revenue of 37,912,427.65 yuan for the third quarter of 2025, representing a year-on-year decline of 13.76% [2] - The net profit attributable to shareholders of the listed company was 4,975,755.59 yuan, showing a significant year-on-year increase of 1361.80% [2] Financial Performance - Revenue for Q3 2025: 37.91 million yuan, down 13.76% year-on-year [2] - Net profit for Q3 2025: 4.98 million yuan, up 1361.80% year-on-year [2]